Literature DB >> 25874350

Anhedonia in depressed patients on treatment with selective serotonin reuptake inhibitor anti-depressant--A two-centered study in Malaysia.

Anne Yee1, Soo Cheng Chin, Aili Hanim bt Hashim, Manveen Kaur A P Harbajan Singh, Huai Seng Loh, Ahmad Hatim Sulaiman, Chong Guan Ng.   

Abstract

OBJECTIVE: Anhedonia is the reduced ability to experience pleasure. It is a core symptom of depression and is particularly difficult to treat. This study aims to compare the level of anhedonia between depressed patients on anti-depressants and healthy subjects.
METHOD: A total of 111 depressed patients on selective serotonin reuptake inhibitor (SSRI) and 82 healthy subjects were recruited from the outpatient psychiatric services at two major general hospitals in a cross-sectional study. Subjects were assessed using the Mini International Neuropsychiatric Interview 5.0.0 or MINI, Beck's Depression Index (BDI), and Snaith-Hamilton Pleasure Scale (SHAPS). Relevant personal and sociodemographic information were also collected.
RESULTS: There was a significant association between educational level and SHAPS-M scores (P < 0.01) among the participants. Most items in the SHAPS scores were significantly different (P < 0.01) in the depressed subjects treated with anti-depressant compared with the healthy subjects, after adjusting the confounding factors, BDI score, and educational level.
CONCLUSION: Anhedonia often persists in depressed patients despite on SSRI anti-depressant treatment.

Entities:  

Keywords:  Anhedonia; depression; selective serotonin reuptake inhibitors

Mesh:

Substances:

Year:  2015        PMID: 25874350     DOI: 10.3109/13651501.2015.1031139

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  6 in total

1.  Cross-sectional networks of depressive symptoms before and after antidepressant medication treatment.

Authors:  Fionneke M Bos; Eiko I Fried; Steven D Hollon; Laura F Bringmann; Sona Dimidjian; Robert J DeRubeis; Claudi L H Bockting
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-04-07       Impact factor: 4.328

Review 2.  Updated Review and Meta-Analysis of Probiotics for the Treatment of Clinical Depression: Adjunctive vs. Stand-Alone Treatment.

Authors:  Viktoriya L Nikolova; Anthony J Cleare; Allan H Young; James M Stone
Journal:  J Clin Med       Date:  2021-02-08       Impact factor: 4.241

3.  Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder.

Authors:  Roger S McIntyre; Henrik Loft; Michael Cronquist Christensen
Journal:  Neuropsychiatr Dis Treat       Date:  2021-02-22       Impact factor: 2.570

4.  Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.

Authors:  Koichiro Watanabe; Shinji Fujimoto; Tatsuro Marumoto; Tadayuki Kitagawa; Kazuyuki Ishida; Tadashi Nakajima; Yoshiya Moriguchi; Keita Fujikawa; Takeshi Inoue
Journal:  Neuropsychiatr Dis Treat       Date:  2022-02-19       Impact factor: 2.570

5.  Editorial. New Targets of Medical Treatment in Psychiatric Disorders.

Authors:  Kunio Yui
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

6.  Response to SSRI intervention and amygdala activity during self-referential processing in major depressive disorder.

Authors:  Kymberly D Young; Edward S Friedman; Amanda Collier; Susan R Berman; Joshua Feldmiller; Agnes E Haggerty; Michael E Thase; Greg J Siegle
Journal:  Neuroimage Clin       Date:  2020-08-20       Impact factor: 4.881

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.